These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 29022489)

  • 1. ADAR1 expression is associated with tumour-infiltrating lymphocytes in triple-negative breast cancer.
    Song IH; Kim YA; Heo SH; Park IA; Lee M; Bang WS; Park HS; Gong G; Lee HJ
    Tumour Biol; 2017 Oct; 39(10):1010428317734816. PubMed ID: 29022489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune-related IncRNA LINC00944 responds to variations in ADAR1 levels and it is associated with breast cancer prognosis.
    de Santiago PR; Blanco A; Morales F; Marcelain K; Harismendy O; Sjöberg Herrera M; Armisén R
    Life Sci; 2021 Mar; 268():118956. PubMed ID: 33383047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MxA expression is associated with tumor-infiltrating lymphocytes and is a prognostic factor in triple-negative breast cancer.
    Kim YA; Lee HJ; Heo SH; Park HS; Park SY; Bang W; Song IH; Park IA; Gong G
    Breast Cancer Res Treat; 2016 Apr; 156(3):597-606. PubMed ID: 27075916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced AZIN1 RNA editing and overexpression of its regulatory enzyme ADAR1 are important prognostic biomarkers in gastric cancer.
    Okugawa Y; Toiyama Y; Shigeyasu K; Yamamoto A; Shigemori T; Yin C; Ichikawa T; Yasuda H; Fujikawa H; Yoshiyama S; Hiro J; Ohi M; Araki T; Kusunoki M; Goel A
    J Transl Med; 2018 Dec; 16(1):366. PubMed ID: 30563560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and prognostic value of anterior gradient protein 2 expression in breast cancer based on tissue microarray.
    Guo J; Gong G; Zhang B
    Tumour Biol; 2017 Jul; 39(7):1010428317713392. PubMed ID: 28671019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating the therapeutic potential of ADAR1 inhibition for triple-negative breast cancer.
    Kung CP; Cottrell KA; Ryu S; Bramel ER; Kladney RD; Bao EA; Freeman EC; Sabloak T; Maggi L; Weber JD
    Oncogene; 2021 Jan; 40(1):189-202. PubMed ID: 33110236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of the MHC class II in triple-negative breast cancer is associated with tumor-infiltrating lymphocytes and interferon signaling.
    Park IA; Hwang SH; Song IH; Heo SH; Kim YA; Bang WS; Park HS; Lee M; Gong G; Lee HJ
    PLoS One; 2017; 12(8):e0182786. PubMed ID: 28817603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ADAR1-mediated RNA-editing of 3'UTRs in breast cancer.
    Sagredo EA; Blanco A; Sagredo AI; Pérez P; Sepúlveda-Hermosilla G; Morales F; Müller B; Verdugo R; Marcelain K; Harismendy O; Armisén R
    Biol Res; 2018 Oct; 51(1):36. PubMed ID: 30290838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcriptome Profiling of ADAR1 Targets in Triple-Negative Breast Cancer Cells Reveals Mechanisms for Regulating Growth and Invasion.
    Baker AR; Miliotis C; Ramírez-Moya J; Marc T; Vlachos IS; Santisteban P; Slack FJ
    Mol Cancer Res; 2022 Jun; 20(6):960-971. PubMed ID: 35247916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune analysis of lymph nodes in relation to the presence or absence of tumor infiltrating lymphocytes in triple-negative breast cancer.
    Quintana Á; Peg V; Prat A; Moliné T; Villacampa G; Paré L; Galván P; Dientsmann R; Schmid P; Curigliano G; Muñoz-Couselo E; Perez-García J; Marti M; Blanco-Heredia J; Anjos CD; Vazquez M; De Mattos-Arruda L; Cortés J
    Eur J Cancer; 2021 May; 148():134-145. PubMed ID: 33743482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased CD4 and CD8-positive T cell infiltrate signifies good prognosis in a subset of triple-negative breast cancer.
    Matsumoto H; Thike AA; Li H; Yeong J; Koo SL; Dent RA; Tan PH; Iqbal J
    Breast Cancer Res Treat; 2016 Apr; 156(2):237-47. PubMed ID: 26960711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glutaminase expression is a poor prognostic factor in node-positive triple-negative breast cancer patients with a high level of tumor-infiltrating lymphocytes.
    Kim JY; Heo SH; Choi SK; Song IH; Park IA; Kim YA; Park HS; Park SY; Bang WS; Gong G; Lee HJ
    Virchows Arch; 2017 Apr; 470(4):381-389. PubMed ID: 28185053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD11c-Positive Dendritic Cells in Triple-negative Breast Cancer.
    Lee H; Lee HJ; Song IH; Bang WS; Heo SH; Gong G; Park IA
    In Vivo; 2018; 32(6):1561-1569. PubMed ID: 30348717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome.
    Beckers RK; Selinger CI; Vilain R; Madore J; Wilmott JS; Harvey K; Holliday A; Cooper CL; Robbins E; Gillett D; Kennedy CW; Gluch L; Carmalt H; Mak C; Warrier S; Gee HE; Chan C; McLean A; Walker E; McNeil CM; Beith JM; Swarbrick A; Scolyer RA; O'Toole SA
    Histopathology; 2016 Jul; 69(1):25-34. PubMed ID: 26588661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential expression of major histocompatibility complex class I in subtypes of breast cancer is associated with estrogen receptor and interferon signaling.
    Lee HJ; Song IH; Park IA; Heo SH; Kim YA; Ahn JH; Gong G
    Oncotarget; 2016 May; 7(21):30119-32. PubMed ID: 27121061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of 150-kDa adenosine deaminase that acts on RNA (ADAR)-1 gene expression in normal T lymphocytes by anti-CD3-epsilon and anti-CD28.
    Laxminarayana D; Khan IU; O'Rourke KS; Giri B
    Immunology; 2007 Dec; 122(4):623-33. PubMed ID: 17897325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combinatory RNA-Sequencing Analyses Reveal a Dual Mode of Gene Regulation by ADAR1 in Gastric Cancer.
    Cho CJ; Jung J; Jiang L; Lee EJ; Kim DS; Kim BS; Kim HS; Jung HY; Song HJ; Hwang SW; Park Y; Jung MK; Pack CG; Myung SJ; Chang S
    Dig Dis Sci; 2018 Jul; 63(7):1835-1850. PubMed ID: 29691780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.
    de Boo L; Cimino-Mathews A; Lubeck Y; Daletzakis A; Opdam M; Sanders J; Hooijberg E; van Rossum A; Loncova Z; Rieder D; Trajanoski Z; Vollebergh M; Sobral-Leite M; van de Vijver K; Broeks A; van der Wiel R; van Tinteren H; Linn S; Horlings HM; Kok M
    Eur J Cancer; 2020 Mar; 127():240-250. PubMed ID: 31956037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ADAR1: a promising new biomarker for esophageal squamous cell carcinoma?
    Qiao JJ; Chan TH; Qin YR; Chen L
    Expert Rev Anticancer Ther; 2014 Aug; 14(8):865-8. PubMed ID: 24928581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined evaluation of the FAS cell surface death receptor and CD8+ tumor infiltrating lymphocytes as a prognostic biomarker in breast cancer.
    Blok EJ; van den Bulk J; Dekker-Ensink NG; Derr R; Kanters C; Bastiaannet E; Kroep JR; van de Velde CJ; Kuppen PJ
    Oncotarget; 2017 Feb; 8(9):15610-15620. PubMed ID: 28121628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.